基于中药整合药理学平台探究开心散治疗AD的物质基础与作用机制

目的:探究开心散治疗阿尔茨海默病的"成分-靶点-疾病"相互关系。方法:利用中药整合药理学平台V1. 0收集开心散所含4味中药的相关活性成分及潜在靶点,并搜索阿尔茨海默病疾病靶标,对其节点(hubs)进行基因本体数据库和京都基因与基因组百科全书数据库富集分析。结果:开心散的250个化合物中有2 877个靶点与阿尔茨海默病相互关联。其中线粒体三功能酶α亚基(HADHA),羟基酰基辅酶A脱氢酶(HADH),甾醇-4-α-羧酸盐3-脱氢酶(NSDHL)等关键靶标主要通过调控嘌呤代谢、核苷酸代谢、亨廷顿氏病、阿尔茨海默病、神经退行性疾病,氧化磷酸化以及内分泌与代谢性疾病等生物过程,在细胞质、线粒体、三磷酸腺苷结合、线粒体基质等分子反应中发挥其药理作用。结论:通过该平台能够预测出开心散治疗阿尔茨海默病的关键靶标及其参与的相关通路,可为深入揭示该复方的物质基础和作用机制提供参考,同时为深入挖掘和开发经典名方开心散提供依据。

Material Basis and Mechanism of Kaixinsan for Treatment of Alzheimer's Disease Based on Integrated Pharmacological Platform of Chinese Medicine

Objective: To explore the interrelation of "composition-target-disease" of Kaixinsan on treatment of Alzheimer''s disease. Method: Through the integrated pharmacological platform of Chinese medicine V1.0,the active ingredients and potential targets of four Chinese herbs in Kaixinsan were collected,disease targets of Alzheimer''s disease were searched,and enriched by the gene ontology database and the Kyoto encyclopedia of genes and genomes at hubs. Result: Among the 250 compounds of Kaixinsan,2 877 targets were associated with Alzheimer''s disease.The key targets,such as mitochondrial trifunctional enzyme subunit alpha(HADHA),hydroxyacyl coenzyme A dehydrogenase(HADH),sterol-4-alpha-carboxylate 3-dehydrogenase(NSDHL) and others,played their pharmacological effects mainly through regulating purine and nucleotide metabolism,Huntington''s disease,Alzheimer''s disease,neurodegenerative diseases,oxidative phosphorylation,and endocrine and metabolic diseases in molecular reactions,such as cytoplasm,mitochondria,adenosine triphosphate binding,and mitochondrial matrix. Conclusion: The platform can predict the key targets and related pathways of Kaixinsan for treatment of Alzheimer''s disease,which lays the foundation for further revealing material basis and mechanism of this formula,and plays an important role in digging and developing this classic and famous formula.